agilon health (AGL) Competitors

$5.41
-0.17 (-3.05%)
(As of 05/17/2024 ET)

AGL vs. PINC, PGNY, SHC, AMPH, RXRX, DNA, DCPH, AMRX, NEO, and KROS

Should you be buying agilon health stock or one of its competitors? The main competitors of agilon health include Premier (PINC), Progyny (PGNY), Sotera Health (SHC), Amphastar Pharmaceuticals (AMPH), Recursion Pharmaceuticals (RXRX), Ginkgo Bioworks (DNA), Deciphera Pharmaceuticals (DCPH), Amneal Pharmaceuticals (AMRX), NeoGenomics (NEO), and Keros Therapeutics (KROS). These companies are all part of the "medical" sector.

agilon health vs.

Premier (NASDAQ:PINC) and agilon health (NYSE:AGL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.

In the previous week, agilon health had 6 more articles in the media than Premier. MarketBeat recorded 13 mentions for agilon health and 7 mentions for Premier. agilon health's average media sentiment score of 0.23 beat Premier's score of 0.08 indicating that Premier is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Premier
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
agilon health
3 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

74.4% of Premier shares are owned by institutional investors. 0.9% of Premier shares are owned by company insiders. Comparatively, 3.2% of agilon health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Premier has a net margin of 6.01% compared to Premier's net margin of -5.67%. agilon health's return on equity of 11.71% beat Premier's return on equity.

Company Net Margins Return on Equity Return on Assets
Premier6.01% 11.71% 7.31%
agilon health -5.67%-26.15%-9.33%

Premier presently has a consensus target price of $23.50, indicating a potential upside of 19.53%. agilon health has a consensus target price of $9.32, indicating a potential upside of 72.30%. Given Premier's stronger consensus rating and higher possible upside, analysts plainly believe agilon health is more favorable than Premier.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Premier
1 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
agilon health
1 Sell rating(s)
12 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.18

Premier received 563 more outperform votes than agilon health when rated by MarketBeat users. Likewise, 69.07% of users gave Premier an outperform vote while only 52.69% of users gave agilon health an outperform vote.

CompanyUnderperformOutperform
PremierOutperform Votes
612
69.07%
Underperform Votes
274
30.93%
agilon healthOutperform Votes
49
52.69%
Underperform Votes
44
47.31%

Premier has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, agilon health has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Premier has higher earnings, but lower revenue than agilon health. agilon health is trading at a lower price-to-earnings ratio than Premier, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Premier$1.34B1.54$175.03M$0.6430.72
agilon health$4.32B0.52-$262.60M-$0.70-7.73

Summary

Premier beats agilon health on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGL vs. The Competition

Metricagilon healthhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE Exchange
Market Cap$2.22B$2.25B$5.23B$18.08B
Dividend YieldN/A1.89%44.24%3.44%
P/E Ratio-7.7315.60119.9624.40
Price / Sales0.525.832,373.9210.66
Price / CashN/A11.4236.8819.24
Price / Book3.243.155.506.00
Net Income-$262.60M$74.19M$105.95M$966.17M
7 Day Performance4.24%-1.56%1.42%1.85%
1 Month Performance-0.73%-2.86%4.96%6.59%
1 Year Performance-75.24%-24.28%7.89%23.69%

agilon health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PINC
Premier
3.622 of 5 stars
$19.41
-6.3%
$25.15
+29.6%
-26.3%$2.33B$1.34B13.962,800Insider Selling
High Trading Volume
PGNY
Progyny
4.1858 of 5 stars
$33.06
+2.0%
$48.30
+46.1%
-21.2%$3.18B$1.09B53.32563Analyst Forecast
News Coverage
SHC
Sotera Health
3.2978 of 5 stars
$11.47
+1.6%
$17.70
+54.3%
-25.0%$3.25B$1.05B60.373,000News Coverage
AMPH
Amphastar Pharmaceuticals
4.8034 of 5 stars
$42.77
+0.2%
$66.00
+54.3%
-0.8%$2.06B$644.40M16.581,761
RXRX
Recursion Pharmaceuticals
1.9871 of 5 stars
$8.79
-1.7%
$12.75
+45.1%
+72.2%$2.06B$44.58M-5.67500Gap Up
DNA
Ginkgo Bioworks
1.8761 of 5 stars
$0.94
-5.0%
$2.20
+133.7%
-39.0%$2.03B$251.46M-2.001,218Analyst Forecast
Insider Buying
Short Interest ↑
News Coverage
DCPH
Deciphera Pharmaceuticals
3.1464 of 5 stars
$25.38
+0.0%
$24.17
-4.8%
+83.3%$2.09B$163.36M-11.08355
AMRX
Amneal Pharmaceuticals
2.128 of 5 stars
$6.51
-2.1%
$8.25
+26.7%
+203.1%$2.00B$2.39B-11.627,700Short Interest ↓
NEO
NeoGenomics
3.2678 of 5 stars
$15.57
+0.4%
$19.78
+27.0%
-17.9%$1.99B$591.64M-23.592,100
KROS
Keros Therapeutics
2.8951 of 5 stars
$58.68
-2.6%
$86.00
+46.6%
+11.9%$2.12B$150,000.00-11.28136

Related Companies and Tools

This page (NYSE:AGL) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners